Extended Data Fig. 5: GNAS signaling in BRAFV600E CRC cell lines and tumors. | Nature Cancer

Extended Data Fig. 5: GNAS signaling in BRAFV600E CRC cell lines and tumors.

From: A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors

Extended Data Fig. 5

a-b, Western blots to detect phospho-T202/Y204 ERK1/2, total ERK1/2, phospho-S217/S221 MEK1/2, total MEK1/2 in BRAFV600E CRC cell lines modified for GNAS expression, and treated with vemurafenib (VEM). The experiment was repeated 2 independent times per cell line with similar results. a, BRAFV600E CRC cell lines engineered with a doxycycline-inducible constitutively active GNAS construct, iGNASR201C with or without doxycycline treatment (+ or – at the bottom of each panel). b, BRAFV600E CRC cell lines knocked out for GNAS using CRISPR (GNAS-KO or CRIPSR control; indicated as + or – at the bottom of each panel). In panels a-b, molecular weight/size markers are indicated on the right (kDa). c, COX2 staining score by IHC in untreated patient CRC tumor specimens with or without a BRAFV600E mutation, from primary (prim.) or metastatic (met.) sites.

Source data

Back to article page